TomoTherapy Announces Pricing of Initial Public Offering
Merrill Lynch & Co. acted as sole-bookrunning manager, Piper Jaffray & Co. acted as co-lead manager, and Thomas Weisel Partners LLC, Robert W. Baird & Co. Incorporated and William Blair & Company acted as co-managers for the offering. The offering will be made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, manufactures and sells the Hi Art® system, an advanced and versatile radiation therapy system for the treatment of a wide variety of cancers. Hi Art® and the TomoTherapy logo are registered trademarks of TomoTherapy Incorporated.
Contact: TomoTherapy Incorporated Patty Kitowski Marketing Communications Manager 608.824.2820 pkitowski@tomotherapy.com
Source: TomoTherapy Incorporated